Jefferson Bridge Capital LLC Invests $1.74 Million in Johnson & Johnson $JNJ

Key Points

• Jefferson Bridge Capital LLC bought a new position of 8,399 shares in Johnson & Johnson valued at about $1.74 million, representing 1.7% of the fund's portfolio and its 23rd largest holding.
• Several large institutions materially increased stakes—Capital International Investors (+545.6%), Marshall Wace (+126.3%), Amundi (+19.3%) and Wellington (now 25.8M shares)—with institutional ownership around 69.6%.
• Analysts are broadly positive: the consensus rating is Moderate Buy with an average target of $238.17, and firms like HSBC and Morgan Stanley have recently raised targets to $280 and $267 respectively.

Jefferson Bridge Capital LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,399 shares of the company's stock, valued at approximately $1,738,000. Johnson & Johnson comprises 1.7% of Jefferson Bridge Capital LLC's investment portfolio, making the stock its 23rd largest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital International Investors lifted its stake in shares of Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company's stock worth $716,657,000 after acquiring an additional 3,266,354 shares during the period. Amundi lifted its stake in shares of Johnson & Johnson by 19.3% in the third quarter. Amundi now owns 13,354,936 shares of the company's stock worth $2,512,719,000 after acquiring an additional 2,163,838 shares during the period. Marshall Wace LLP lifted its stake in shares of Johnson & Johnson by 126.3% in the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock worth $664,575,000 after acquiring an additional 2,000,609 shares during the period. Danske Bank A S acquired a new position in shares of Johnson & Johnson in the third quarter worth approximately $367,467,000. Finally, Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 3.8% in the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock worth $4,789,914,000 after acquiring an additional 956,239 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HSBC lifted their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a "buy" rating in a research note on Tuesday, March 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $255.00 price objective on shares of Johnson & Johnson in a research note on Monday, March 30th. Leerink Partners lifted their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the stock a "market perform" rating in a research note on Thursday, January 22nd. Scotiabank reaffirmed an "outperform" rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Johnson & Johnson in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $238.17.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company's stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Morgan Stanley raised its price target to $267 and kept an "Overweight" rating, signaling roughly double-digit upside versus current levels and supporting buy-side interest. Read More.
• Positive Sentiment: Other broker notes (Guggenheim, Citi, and various upgrades) have recently pushed bullish research and helped intraday rallies. Read More.
• Positive Sentiment: Commercial/MedTech catalyst — J&J launched the VARIPULSE Pro pulsed field ablation system in Europe after CE mark approval, adding potential device revenue upside and real‑world evidence generation. Read More.
• Positive Sentiment: Dividend profile remains a tailwind for income investors — long streak of annual increases (>60 years) supports total‑return buyers. Read More.
• Neutral Sentiment: Fair‑value/target updates are moving modestly (consensus fair value around ~$241.7) — analysts are lifting some targets while flagging execution as the next focus, keeping valuation views mixed. Read More.
• Neutral Sentiment: Market is positioning for Q1 earnings — multiple previews and Wall Street estimate rundowns are circulating; that typically increases volatility into the print. Read More.
• Negative Sentiment: Some analysts and commentators are cautioning that this is “time to sell the rally” into Q1, arguing upside expectations may be priced in and that near‑term catalysts could disappoint. Read More.
• Negative Sentiment: Ongoing risks — litigation exposure, biosimilar competition and pricing pressure are repeatedly flagged as potential earnings/headwind items that could cap upside. Read More.

Johnson & Johnson Trading Down 1.2%

NYSE JNJ opened at $238.34 on Friday. The company has a market cap of $574.06 billion, a price-to-earnings ratio of 21.57, a P/E/G ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71. The business has a 50 day moving average price of $241.29 and a 200-day moving average price of $214.99. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.